EUCTR2017-002137-32-SE进行中（未招募）1 期
Immunological responses after concomitant vaccination with the yellow fever-vaccine Stamaril and the TBE-vaccine FSME Immun, or JE-vaccine Ixiaro
Hans-Gustaf Ljunggren0 个研究点目标入组 140 人开始时间: 2017年7月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Individuals that need prevention of TBE, Yellow fever and JE
- •Induviduals that signed informed concent
- •Individuals between 18-55 years of age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Individuals that:
- •Claim that they already had vaccination, or been infected with TBE, JE or Yellow fever
- •Are allergic to eggs or something else in FSME Immun, Stamaril and Ixiaro
- •Have an autoimmune disease
- •Have difficulties donating blood
- •Take drugs against cancer
- •Take corticosteroids
- •Have a disease that had affected the brain
- •Have neurological disorders
- •Have dampened immune function or that of other reason is evaluated by the investigator as inappropriate for inclusion
- •Have HCV or HIV
- •Had fever within a week from the time of vaccination
- •Are pregnant or plan to be pregnant in the course of the study
- •Have a bleeding disorder
- •Participated in other clinical trials within the last three months
- •Cannot fulfill the study
- •Or for other reasons is evaluated not to be suitable for inclusion
研究者
相似试验
进行中（未招募）
不适用
Safety and immunogenicity of concomitant vaccination with IC51 and Havrix 1440 in healthy subjects. A single-blind randomised, controlled phase 3 study.EUCTR2005-003526-25-DEIntercell AG192
进行中（未招募）
1 期
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.EUCTR2022-004118-12-ATMedical University of Vienna256
进行中（未招募）
不适用
A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACThe vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10046859Term: VaccinationEUCTR2009-011523-31-GBR & D, Cambridge University Hospitals60
进行中（未招募）
不适用
Etude des réponses immunitaires après vaccination anit-influenza saisonnier et anti-H1N1 variant pandémique dans une population de personnel soignant. - FLU-HOPsymptome de la grippeMedDRA version: 12.0Level: LLTClassification code 10016797Term: Flu-like symptomsEUCTR2009-016267-11-FRInserm
已完成
不适用
The efficacy of the combination of allergen vaccination and vitamin D3 in the reduction of allergen-specific nasal responses. A placebo controlled trial.RespiratoryVasomotor and allergic rhinitisRhinitisISRCTN42318360Academic Medical Centre (AMC) (Netherlands)90